ADMA Biologics, Inc. (ADMA): Free Cash Flow
$27.82M
Year ended 2025-12-31
$116.47M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $27.82M | -74.8% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $110.45M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $4.03M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$73.42M | n/m | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | -$125.88M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$114.73M | n/m | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | -$80.01M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$64.77M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$39.95M | n/m | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | -$18.34M | n/m | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | -$15.44M | n/m | 2017-02-24, From 2015-01-01 |
| 2014-12-31 | -$17.03M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | -$11.08M | n/m | 2015-03-09, From 2013-01-01 |
| 2012-12-31 | -$7.02M | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$1.43M | n/a | 2013-03-06, From 2011-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $27.82M | -74.8% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | -$22.31M | n/m |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$15.05M | n/m |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $188.91M | +58.5% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$75.63M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $93.90M | -37.3% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $344.90M | n/m |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$48.95M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $24.75M | n/m |
Compare ADMA, TARS, IMCR, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗